Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
NCT06568042 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3848575
Study Locations (20)
Florida
- Accel Research Sites - St. Pete-Largo Clinical Research Unit — Largo
- Design Neuroscience Center — Miami Lakes
- Conquest Research - Orlando — Orlando
- Charter Research - Lady Lake — The Villages
- Encore Medical Research - Weston — Weston
- Conquest Research — Winter Park
Arizona
- MD First Research - Chandler — Chandler
- HOPE Research Institute — Phoenix
New York
- Mid Hudson Medical Research — New Windsor
- University of Rochester Medical Center — Rochester
North Carolina
- Asheville Neurology Specialists, PA — Asheville
- Center for Clinical Research — Winston-Salem
California
- Neuro-Pain Medical Center — Fresno
Colorado
- Alpine Clinical Research Center — Boulder
Iowa
- Integrated Clinical Trial Services, Inc. — West Des Moines
Massachusetts
- Lucida Clinical Trials — New Bedford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06568042
The ClinicalTrials.gov registry entry for NCT06568042 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Neuropathic Pain appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06568042 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Arizona, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06568042 about?
NCT06568042 is a clinical study titled "Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy". The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee. Participation may last up to 30 weeks including screening.
What is the current status of trial NCT06568042?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 450 participants. The study started on 2024-08-22. Estimated completion is 2026-09.
What conditions does trial NCT06568042 study?
This clinical trial studies the following conditions: Neuropathic Pain, Distal Sensory Polyneuropathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06568042?
The interventions under investigation include: Placebo (DRUG), LY3848575 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06568042?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06568042 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.